Protective effects of the novel adenosine derivative WS0701 in a mouse model of posttraumatic stress disorder

Huang, Zhonglin; Li, Rui; Bai, Xiaoyu; Zhao, Guoqiang; Song, Junke; Wu, Song; Du, Guanhua

doi:10.1038/aps.2013.143

Cited by 24 publications

(9 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the interpretation of these results is confounded by re-exposure to water, which is a reminder of the stressor in SPS-exposed rats but not controls ( 106 ) and so may affect performance in this task. We and others have also observed impairment in object recognition ( 148 , 149 ) and social discrimination ( 148 ). This impairment in social discrimination may be attributed to decreased behavioral flexibility, a notion corroborated by evidence that SPS decreases performance in set shifting tasks ( 150 – 152 ).…”

Section: Behavioral Effects Of Spssupporting

confidence: 61%

Single-Prolonged Stress: A Review of Two Decades of Progress in a Rodent Model of Post-traumatic Stress Disorder

et al. 2018

View full text Add to dashboard Cite

Post-traumatic stress disorder (PTSD) is a common, costly, and often debilitating psychiatric condition. However, the biological mechanisms underlying this disease are still largely unknown or poorly understood. Considerable evidence indicates that PTSD results from dysfunction in highly-conserved brain systems involved in stress, anxiety, fear, and reward. Pre-clinical models of traumatic stress exposure are critical in defining the neurobiological mechanisms of PTSD, which will ultimately aid in the development of new treatments for PTSD. Single prolonged stress (SPS) is a pre-clinical model that displays behavioral, molecular, and physiological alterations that recapitulate many of the same alterations observed in PTSD, illustrating its validity and giving it utility as a model for investigating post-traumatic adaptations and pre-trauma risk and protective factors. In this manuscript, we review the present state of research using the SPS model, with the goals of (1) describing the utility of the SPS model as a tool for investigating post-trauma adaptations, (2) relating findings using the SPS model to findings in patients with PTSD, and (3) indicating research gaps and strategies to address them in order to improve our understanding of the pathophysiology of PTSD.

show abstract

Section: Behavioral Effects Of Spssupporting

confidence: 61%

Single-Prolonged Stress: A Review of Two Decades of Progress in a Rodent Model of Post-traumatic Stress Disorder

et al. 2018

View full text Add to dashboard Cite

show abstract

“…A 2A R mediated increased interleukin (IL)-1β in the brain contributed to anxiety ( Chiu et al, 2014 ). Fear and anxiety in a mouse model of post-traumatic stress disorder were alleviated by administration of a derivative of adenosine, WS0701 ( Huang et al, 2014 ). A 1 R agonists have been used to treat anxiety, but have troublesome side-effects so positive allosteric modulators have been developed as potent anxiolytic agents ( Vincenzi et al, 2016 ).…”

Section: Disorders Of the Central Nervous System (Cns)mentioning

confidence: 99%

Purinergic Signalling: Therapeutic Developments

2017

View full text Add to dashboard Cite

Purinergic signalling, i.e., the role of nucleotides as extracellular signalling molecules, was proposed in 1972. However, this concept was not well accepted until the early 1990’s when receptor subtypes for purines and pyrimidines were cloned and characterised, which includes four subtypes of the P1 (adenosine) receptor, seven subtypes of P2X ion channel receptors and 8 subtypes of the P2Y G protein-coupled receptor. Early studies were largely concerned with the physiology, pharmacology and biochemistry of purinergic signalling. More recently, the focus has been on the pathophysiology and therapeutic potential. There was early recognition of the use of P1 receptor agonists for the treatment of supraventricular tachycardia and A2A receptor antagonists are promising for the treatment of Parkinson’s disease. Clopidogrel, a P2Y12 antagonist, is widely used for the treatment of thrombosis and stroke, blocking P2Y12 receptor-mediated platelet aggregation. Diquafosol, a long acting P2Y2 receptor agonist, is being used for the treatment of dry eye. P2X3 receptor antagonists have been developed that are orally bioavailable and stable in vivo and are currently in clinical trials for the treatment of chronic cough, bladder incontinence, visceral pain and hypertension. Antagonists to P2X7 receptors are being investigated for the treatment of inflammatory disorders, including neurodegenerative diseases. Other investigations are in progress for the use of purinergic agents for the treatment of osteoporosis, myocardial infarction, irritable bowel syndrome, epilepsy, atherosclerosis, depression, autism, diabetes, and cancer.

show abstract

“…Adenosine, via A2A receptors, increased interleukin 1 in the brain contributing to anxiety [118]. Administration of a derivative of adenosine, WS0701, alleviated anxiety and fear in a mouse model of posttraumatic stress disorder [119]. In the aetiology of anxiety disorders and addiction, the basolateral amygdala plays a critical role and adenosine, via activation of A2A receptors, facilitated basolateral amygdala pyramidal cell output [120].…”

Section: Mood Disordermentioning

confidence: 99%

Purinergic Signalling and Neurological Diseases: An Update

Burnstock

2017

CNSNDDT

104

View full text Add to dashboard Cite

Purinergic signalling, i.e. ATP as an extracellular signalling molecule and cotransmitter in both peripheral and central neurons, is involved in the physiology of neurotransmission and neuromodulation. Receptors for purines have been cloned and characterised, including 4 subtypes of the P1(adenosine) receptor family, 7 subtypes of the P2X ion channel nucleotide receptor family and 8 subtypes of the P2Y G protein-coupled nucleotide receptor family. The roles of purinergic signalling in diseases of the central nervous system and the potential use of purinergic compounds for their treatment are attracting increasing attention. In this review, the focus is on the findings reported in recent papers and reviews to update knowledge in this field about the involvement of purinergic signalling in Alzheimer's, Parkinson's and Huntington's diseases, multiple sclerosis, amyotrophic lateral sclerosis, degeneration and regeneration after brain injury, stroke, ischaemia, inflammation, migraine, epilepsy, psychiatric disorders, schizophrenia, bipolar disorder, autism, addiction, sleep disorders and brain tumours. The use in particular of P2X7 receptor antagonists for the treatment of neurodegenerative diseases, cancer, depression, stroke and ischaemia, A2A receptor antagonists for Parkinson's disease and agonists for brain injury and depression and P2X3 receptor antagonists for migraine and seizures has been recommended. P2Y receptors have also been claimed to be involved in some central nervous disorders.

show abstract

Protective effects of the novel adenosine derivative WS0701 in a mouse model of posttraumatic stress disorder

Cited by 24 publications

References 23 publications

Single-Prolonged Stress: A Review of Two Decades of Progress in a Rodent Model of Post-traumatic Stress Disorder

Single-Prolonged Stress: A Review of Two Decades of Progress in a Rodent Model of Post-traumatic Stress Disorder

Purinergic Signalling: Therapeutic Developments

Purinergic Signalling and Neurological Diseases: An Update

Contact Info

Product

Resources

About